2020
Abstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients
Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Karlin-Neumann G, Polsky D, Chi A. Abstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients. Clinical Cancer Research 2020, 26: a65-a65. DOI: 10.1158/1557-3265.liqbiop20-a65.Peer-Reviewed Original ResearchCell-free circulating tumor DNAPlasma cell-free circulating tumor DNADroplet digital PCRTumor DNAClinical outcomesDroplet digital PCR assayGBM patientsC228TC250TTERT mutationsIDHwt glioblastomasPlasma samplesLiquid biopsyPost-RT follow-upPromoter mutations C228TTERT promoter hotspot mutationsNewly diagnosed GBM patientsAssociated with clinical outcomesMonitoring of glioblastomaMonths post radiationDiagnosed glioblastoma patientsGross total resectionPromoter hotspot mutationsIDH wild-typeFFPE tumor samples
2019
NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS
Mureb M, Jain R, Poisson L, Littig I, Neto L, Wu C, Ng V, Patel S, Patel S, Serrano J, Kurz S, Cahill D, Bendszus M, von Deimling A, Placantonakis D, Golfinos J, Kickingereder P, Snuderl M, Chi A. NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology 2019, 21: vi163-vi163. PMCID: PMC6847952, DOI: 10.1093/neuonc/noz175.681.Peer-Reviewed Original ResearchCDKN2A/B homozygous deletionCopy number variationsHomozygous deletionHigher rCBVGenomic alterationsRelative cerebral blood volumeImmediate postoperative settingHigh perfusion areaCopy number statusCerebral blood volumeNon-invasive imaging biomarkerInformed treatment decisionsMalignant genotypePostoperative settingIDHwt glioblastomasRCBVCDKN2A/BIDHmutCNV analysisAstrocytomaBlood volumeTreatment decisionsPerfusion areaImaging biomarkersDNA hypomethylationPlasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays.
Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Shao Y, Karlin-Neumann G, Polsky D, Chi A. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Journal Of Clinical Oncology 2019, 37: 2026-2026. DOI: 10.1200/jco.2019.37.15_suppl.2026.Peer-Reviewed Original ResearchCell-free circulating tumor DNADroplet digital PCR assayDroplet digital PCRCtDNA levelsTERT mutationsPharmacodynamic biomarkersPlasma cell-free circulating tumor DNATERT promoter hotspot mutationsTERT promoter mutationsPromoter hotspot mutationsFFPE tumor samplesUnresected glioblastomaC228TPreoperative MRIIDH-wildtypeTumor DNADigital PCR assayIDHwt glioblastomasClinical stabilityTumor mutationsClinical outcomesClinical associationsGlioblastoma patientsHotspot mutationsTumor samples